ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy

NCT00508430 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

199

Enrollment

INDUSTRY

Sponsor class

Stopped An independent DMC determined continuation was unlikely to demonstrate a statistically significant advantage of ASP8825 over placebo on the primary endpoint

Conditions

Diabetic Neuropathies

Interventions

DRUG: ASP8825
DRUG: Placebo

Sponsor

Astellas Pharma Inc